Skip to main
JNJ
JNJ logo

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 31%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's innovative medicine division generated revenues of $15.20 billion, reflecting a 2.4% year-over-year increase, which surpassed consensus expectations, indicating strong demand particularly in immunology, oncology, and neurology. Management has raised FY25 reported sales guidance to a range of $93.2–$93.6 billion, supported by approximately $900 million from operational growth and $1.1 billion attributable to favorable currency exchange rates, underscoring the firm's robust financial performance. Additionally, total operational sales growth is expected to accelerate in the second half of 2025 and into 2026, suggesting positive momentum for both top-line and bottom-line growth moving forward.

Bears say

Johnson & Johnson's stock outlook appears negative primarily due to expected revenue pressures from the pharmaceutical pipeline, with projections indicating potential sales declines below $57B by 2025 due to lower contributions and loss of exclusivity for key products. The MedTech division faces significant competitive headwinds and an uncertain integration from mergers and acquisitions, which could hinder expected product uptake and overall growth. Furthermore, increased litigation costs and the unpredictability within the MedTech segment contribute to an unfavorable growth environment, raising concerns for the company's financial stability in the near future.

JNJ has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 31% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 16 analysts, JNJ has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $191.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $191.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.